Prosecution Insights
Last updated: April 19, 2026

Crispr Therapeutics AG

9 pending office actions

Portfolio Summary

9
Total Pending OAs
4
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18444368 COMPOSITIONS AND METHODS FOR GENE EDITING HOLLAND, PAUL J 1656 Final Rejection Feb 16, 2024
18188406 ANTI-CD83 CAR-T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION METCALF, MATTHEW CURRAN 1647 Non-Final OA Mar 22, 2023
18181135 MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY BARRERA, IMMACULADA 1671 Non-Final OA Mar 09, 2023
17934799 HIGH PURITY gRNA SYNTHESIS PROCESS ZARA, JANE J 1637 Final Rejection Sep 23, 2022
17933369 UNIVERSAL DONOR CELLS QIAN, CELINE X 1637 Non-Final OA Sep 19, 2022
17906471 T-CELL BISPECIFIC BINDING PROTEINS OGUNBIYI, OLUWATOSIN A 1645 Non-Final OA Sep 15, 2022
17904002 ANTI-IDIOTYPE ANTIBODIES TARGETING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR BUNNER, BRIDGET E 1647 Non-Final OA Aug 10, 2022
17491761 MATERIALS AND METHODS FOR ENGINEERING CELLS AND USES THEREOF IN IMMUNO-ONCOLOGY VIJAYARAGHAVAN, JAGAMYA NMN 1633 Final Rejection Oct 01, 2021
16488149 COMPOSITIONS AND METHODS FOR TREATMENT OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)-RELATED DISORDERS CLARKE, TRENT R 1651 Final Rejection Aug 22, 2019

Managing Crispr Therapeutics AG's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month